Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
Tilray Brands' fiscal Q1 2027 results show beverage revenue up 82% and European medical cannabis growth offsetting weaker Canadian sales, reducing reliance on U.S. federal rescheduling.
MarketBeat ·